• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Robust Guidelines for the Management of HR+ Her2- EBC: Crucial Value of CanAssist Breast.

作者信息

Vaid Ashok, T Raja, Batra Ullas, Krishna Vamshi Muddu, Rangrajan Bharath, Narayanan Prasad, Vora Amish, Advani Suresh H

机构信息

Department of Medical & HematoOncology, Cancer Institute, Medanta Hospital, Gurugram, Haryana, India.

Department of Medical Oncology & BMT, Apollo Hospital, Chennai, Tamil Nadu, India.

出版信息

South Asian J Cancer. 2022 Aug 23;11(2):95-96. doi: 10.1055/s-0042-1756179. eCollection 2022 Apr.

DOI:10.1055/s-0042-1756179
PMID:36466976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9718594/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90ec/9718594/199c894bedde/10-1055-s-0042-1756179-iv11n2editorial-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90ec/9718594/199c894bedde/10-1055-s-0042-1756179-iv11n2editorial-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90ec/9718594/199c894bedde/10-1055-s-0042-1756179-iv11n2editorial-1.jpg

相似文献

1
Robust Guidelines for the Management of HR+ Her2- EBC: Crucial Value of CanAssist Breast.HR+ Her2-早期乳腺癌管理的稳健指南：CanAssist Breast的关键价值
South Asian J Cancer. 2022 Aug 23;11(2):95-96. doi: 10.1055/s-0042-1756179. eCollection 2022 Apr.
2
Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.CanAssist-Breast 的分析验证：一种基于免疫组织化学的激素受体阳性乳腺癌患者预后检测方法。
BMC Cancer. 2019 Mar 20;19(1):249. doi: 10.1186/s12885-019-5443-5.
3
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.CanAssist Breast 在欧洲早期乳腺癌患者队列中的回顾性验证。
Breast. 2022 Jun;63:1-8. doi: 10.1016/j.breast.2022.02.010. Epub 2022 Feb 22.
4
Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.芬兰西南部医院区乳腺癌生物学亚组的真实世界临床结局
Oncologist. 2021 Aug;26(8):e1372-e1380. doi: 10.1002/onco.13813. Epub 2021 Jun 1.
5
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.在 55 岁及以上的雌激素受体阳性乳腺癌患者中，中等水平的 HER2 表达与不良预后相关。
Breast Cancer Res Treat. 2020 Feb;179(3):687-697. doi: 10.1007/s10549-019-05505-4. Epub 2019 Dec 6.
6
The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.CanAssist 乳腺在评估印度裔患者复发风险中的作用。
Breast. 2021 Oct;59:1-7. doi: 10.1016/j.breast.2021.05.007. Epub 2021 May 28.
7
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.生物类似药曲妥珠单抗（CT-P6）在HER2阳性早期和转移性乳腺癌中的真实世界临床疗效
Front Oncol. 2021 Jun 4;11:689587. doi: 10.3389/fonc.2021.689587. eCollection 2021.
8
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.曲妥珠单抗在资源有限或资源丰富地区的使用差异及其对 HER2 阳性乳腺癌的生存获益：来自中国的真实世界研究。
Oncologist. 2017 Nov;22(11):1333-1338. doi: 10.1634/theoncologist.2017-0088. Epub 2017 Aug 10.
9
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.赫赛汀（曲妥珠单抗）治疗人表皮生长因子受体 2 阳性早期乳腺癌：一项系统评价和累积网络荟萃分析。
Syst Rev. 2018 Nov 14;7(1):191. doi: 10.1186/s13643-018-0854-y.
10
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.CDK4/6 抑制剂作为激素受体阳性、HER2 阴性早期乳腺癌的辅助治疗：系统评价和荟萃分析。
ESMO Open. 2021 Apr;6(2):100091. doi: 10.1016/j.esmoop.2021.100091. Epub 2021 Mar 18.

本文引用的文献

1
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.印度HR阳性、Her2阴性早期乳腺癌患者化疗风险与获益优化的实用共识建议
South Asian J Cancer. 2021 Dec 31;10(4):213-219. doi: 10.1055/s-0041-1742080. eCollection 2021 Dec.
2
South Asian Declaration-Consensus Guidelines for COVID-19 Vaccination in Cancer Patients.《南亚声明——癌症患者新冠疫苗接种共识指南》
South Asian J Cancer. 2021 Jan;10(1):3-8. doi: 10.1055/s-0041-1731909. Epub 2021 Aug 20.
3
IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?
免疫组织化学（IHC）与荧光原位杂交（FISH）与下一代测序（NGS）检测非小细胞肺癌（NSCLC）中的 ALK 基因重排：所有问题都有答案了吗？
J Clin Pathol. 2022 Jun;75(6):405-409. doi: 10.1136/jclinpath-2021-207408. Epub 2021 Mar 22.
4
Shared Decision-Making and Medicolegal Aspects: Delivering High-Quality Cancer Care in India.共同决策与法医学方面：在印度提供高质量癌症护理
Indian J Palliat Care. 2020 Oct-Dec;26(4):405-410. doi: 10.4103/IJPC.IJPC_237_19. Epub 2020 Nov 19.
5
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.随机化 TAILORx 试验中激素受体阳性、HER2 阴性、淋巴结阴性乳腺癌的种族、民族与临床结局
J Natl Cancer Inst. 2021 Apr 6;113(4):390-399. doi: 10.1093/jnci/djaa148.
6
A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery.一项来自印度的 3453 例非转移性乳腺癌患者接受初始手术的多机构真实世界数据研究。
Sci Rep. 2020 Apr 3;10(1):5886. doi: 10.1038/s41598-020-62618-3.
7
Oncotype DX: Where Does It Stand in India?肿瘤基因检测（Oncotype DX）：在印度的现状如何？
J Glob Oncol. 2019 Jul;5:1-2. doi: 10.1200/JGO.19.00151.
8
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.基于免疫组织化学的 CanAssist-Breast 试验对激素受体阳性乳腺癌患者远处复发预测的临床验证。
Cancer Med. 2019 Apr;8(4):1755-1764. doi: 10.1002/cam4.2049. Epub 2019 Mar 7.
9
Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.用于早期激素受体阳性乳腺癌患者预后评估的新型蛋白质组学风险分类器的开发
Biomark Insights. 2018 Jul 30;13:1177271918789100. doi: 10.1177/1177271918789100. eCollection 2018.